Skip to main content
Biotech
Aclaris stock halves after phase 2a skin study misses goals
Previous PostBitcoin traders eye $19K BTC price bottom, warn of 'hot' February CPI
Next PostTo 'keep pace with viral evolution,' Invivyd is also evolving (again)
